The IPPaM Study - Does Light-Therapy Reduce Osteoarthritis Knee Pain and Aid Willingness to Exercise?

Osteoarthritis of the knee joint

Associate Professor Liisa Laakso is testing the effectiveness of a new light-emitting adhesive patch that shines red and blue light to the knee joint and thigh muscle. Ten participants apply four “light patches” to the leg for 30 minutes a day for two weeks. Ten other participants receive no light therapy.

On several occasions throughout the study the researchers ask participants to do simple physical tests, and answer questionnaires about their pain and other symptoms.

Prof. Laakso aims to recruit 20 people to the study from the Mater Hospital Brisbane Physiotherapy waitlist.

Information from this study will inform the development of future research.

Category
Trial Status
Recruiting
Trial Phase
Medical Device Post-Market Study
Trial contact details
Contact Person
A/Prof Liisa Laakso
What you need to know

Who can take part?

  • People aged between 50 and 87 years old
  • People with knee osteoarthritis currently on the Mater Hospital Brisbane waitlist for physiotherapy.
  • Not currently on a surgical waitlist for a total knee replacement
  • No pre-existing problems of pronounced weakness or poor sensation in the leg.

What is involved for you?

  • Our study is evaluating a device which emits red and blue light (non-laser) for treatment purposes, and which has been approved by the Therapeutic Goods Administration.
  • After being given instructions on use and care, participants who are randomised to receive light treatment will apply the light patches daily at home for 2 weeks
  • All participants are asked to do a series of simple physical tests, and complete several questionnaires, on up to 7 occasions throughout the study
  • The final assessment is 6 months after the initial assessment
  • The researchers can visit the participant in their home, workplace, or at the Mater Hospital Brisbane Physiotherapy clinic

Trial dates 

This trial is accepting participants until July 2023.

All research clinical trials news

2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.

29

Feb

Highlighting Mater Research’s year of achievements: 2023 Annual Report

When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.

27

Oct

Clinical trials give Queensland breast cancer patients hope

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.

23

May

Mater launches trial of Australian-first flu vaccine

Displaying results 1-3 (of 18)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|